🇺🇸 FDA
Patent

US 8530167

Diagnostic and therapeutic uses of GNPTAB, GNPTG, and NAGPA in stuttering

granted A61PA61P43/00

Quick answer

US patent 8530167 (Diagnostic and therapeutic uses of GNPTAB, GNPTG, and NAGPA in stuttering) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 10 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61P, A61P43/00